LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that a pivotal study on the safety and efficacy of Elestrin™ (estradiol gel) in the treatment of menopausal symptoms has been published in the March issue of Obstetrics & Gynecology, the primary journal of the American College of Obstetricians and Gynecologists (ACOG). The paper titled "Low Dose of Transdermal Estradiol (E2) Gel for Treatment of Symptomatic Postmenopausal Women," reports on a 12-week, double-blind, placebo-controlled Phase III study of 484 symptomatic menopausal women, which was designed to identify the lowest safe and effective dose of transdermal estradiol therapy. The lead investigator for the multicenter study was Dr. James A. Simon, Director of the Women's Health Research Center in Washington, D.C.
